Effect of the SCL16A11 Risk Haplotype on Treatments to Prevent Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 437 participants.
Also called NCT05990205
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 437 participants
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Registry
-
NCT05990205
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Mexico
- Registry status
- Completed
Technical summary
Registry record NCT05990205. Randomized; no masking; primary purpose prevention. Start 2018-04-17 (actual); primary completion 2023-12-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of the SCL16A11 Risk Haplotype on Treatments to Prevent Type 2 Diabetes
- Acronym
- PRED2
- Condition
- PreDiabetes
- Intervention (Drug)
- Life Style Intervention + Metformin
- Intervention (Behavioral)
- Life Style Intervention
- Lead sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Record details
- Record id
cardio:ct-nct05990205- Content hash
cf8c980e1629a64d0ef8a37d1c58a9dc17ec93e595477752410b4aa21ddfe397